GoodRx Files 8-K on Operations & Financial Condition
Ticker: GDRX · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1809519
| Field | Detail |
|---|---|
| Company | Goodrx Holdings, Inc. (GDRX) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-filing
TL;DR
**GoodRx just dropped an 8-K about its financials, get ready for potential stock movement.**
AI Summary
GoodRx Holdings, Inc. filed an 8-K on January 10, 2024, primarily to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that the company is providing an update on its financial performance and operational status. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock's valuation and future outlook, potentially leading to price volatility as the market digests the details.
Why It Matters
This filing signals that GoodRx is releasing new financial information, which is crucial for investors to assess the company's health and make informed decisions about buying, holding, or selling the stock.
Risk Assessment
Risk Level: medium — The risk level is medium because while the filing itself is procedural, the undisclosed financial details could contain positive or negative surprises impacting the stock.
Analyst Insight
A smart investor would await the full details of the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' mentioned in this 8-K before making any investment decisions, as these will provide the specific financial data impacting the company's valuation.
Key Players & Entities
- GoodRx Holdings, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where GoodRx's Class A Common Stock is registered
- January 10, 2024 (date) — the date of the earliest event reported and the filing date
- $0.0001 (dollar_amount) — par value per share of Class A Common Stock
FAQ
What is the primary purpose of GoodRx Holdings, Inc.'s 8-K filing dated January 10, 2024?
The primary purpose of GoodRx Holdings, Inc.'s 8-K filing dated January 10, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and the exchange where GoodRx Holdings, Inc.'s Class A Common Stock is registered?
GoodRx Holdings, Inc.'s Class A Common Stock has the trading symbol 'GDRX' and is registered on 'The Nasdaq Stock Market LLC', as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the address of GoodRx Holdings, Inc.'s principal executive offices?
The address of GoodRx Holdings, Inc.'s principal executive offices is '2701 Olympic Boulevard Santa Monica, California 90404', as listed in the filing.
What is the par value per share of GoodRx Holdings, Inc.'s Class A Common Stock?
The par value per share of GoodRx Holdings, Inc.'s Class A Common Stock is '$0.0001', as indicated in the 'Title of each class' section for registered securities.
Is GoodRx Holdings, Inc. considered an emerging growth company according to this 8-K filing?
The filing includes a checkbox '☐ Indicate by check mark whether the registrant is an emerging growth company', but it is not checked, implying that GoodRx Holdings, Inc. does not currently identify as an emerging growth company for the purposes of this filing.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-01-10 09:00:19
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share GDRX The Nasdaq Sto
Filing Documents
- gdrx-20240110.htm (8-K) — 26KB
- a010824-gdrxxpressreleasep.htm (EX-99.1) — 41KB
- a1.jpg (GRAPHIC) — 40KB
- 0001809519-24-000006.txt ( ) — 255KB
- gdrx-20240110.xsd (EX-101.SCH) — 2KB
- gdrx-20240110_lab.xml (EX-101.LAB) — 24KB
- gdrx-20240110_pre.xml (EX-101.PRE) — 12KB
- gdrx-20240110_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 10, 2024, GoodRx Holdings, Inc. (the "Company") issued a press release announcing the Company's preliminary estimates of certain financial results for the three months and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. These preliminary financial results are unaudited, based on the Company's current estimate of its results for the three months and year ended December 31, 2023, and remain subject to change based on the completion of closing and review procedures and the execution of the Company's internal control over financial reporting. The information in Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are included with this Current Report on Form 8-K: 99.1* Press Release, dated January 10 , 2024. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. * Furnished herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOODRX HOLDINGS, INC. Date: January 10, 2024 By: /s/ Karsten Voermann Name: Karsten Voermann Title: Chief Financial Officer